Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 6, pp 931–936

Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study

  • Eric François
  • Jean-François Berdah
  • Emmanuel Chamorey
  • Gérard Lesbats
  • Eric Teissier
  • Jean-François Codoul
  • Jean-Luc Badetti
  • Christophe Hébert
  • Véronique Mari
Original Article

DOI: 10.1007/s00280-008-0681-2

Cite this article as:
François, E., Berdah, JF., Chamorey, E. et al. Cancer Chemother Pharmacol (2008) 62: 931. doi:10.1007/s00280-008-0681-2

Abstract

Background

The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer.

Patients and methods

Patients with metastatic colorectal cancer included in this study were aged at least 70 years, with a performance status of 0/1, without geriatric syndrome and without previous palliative chemotherapy. They received irinotecan [180 mg/m2 intravenous (iv) infusion over 90 min] followed by folinic acid (400 mg/m2 iv over 2 h), then 5FU (400 mg/m2 iv bolus) and 5FU (2,400 mg/m2 continuous iv infusion for 46 h) every 2 weeks.

Results

Forty eligible patients were included. The median age was 77.3 years (range 70–84.7). The objective response rate was 40% and the stabilisation rate was 45%. Median progression-free survival was 8 months, overall survival was 17.2 months and cancer-related specific survival was 20.2 months. In total, 300 cycles of chemotherapy were administered with a median number of eight cycles per patient (range 1–18). Tolerance was good; grade 3/4 toxicities included diarrhoea (15%), asthenia (15%), nausea/vomiting (7.5%) and neutropenia (7.5%). One toxic death was observed due to grade 4 diarrhoea.

Conclusion

The FOLFIRI 1 regimen is a valid therapeutic option for elderly patients in good clinical condition.

Keywords

Colorectal cancerElderlyIrinotecan5-FluorouracilPhase II

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Eric François
    • 1
  • Jean-François Berdah
    • 2
  • Emmanuel Chamorey
    • 1
  • Gérard Lesbats
    • 3
  • Eric Teissier
    • 4
  • Jean-François Codoul
    • 5
  • Jean-Luc Badetti
    • 6
  • Christophe Hébert
    • 1
  • Véronique Mari
    • 1
  1. 1.Centre Antoine-LacassagneNice Cedex 2France
  2. 2.Clinique de l’EspéranceHyèresFrance
  3. 3.Clinique Saint-LaurentSaint Laurent du VarFrance
  4. 4.Clinique Plein CielMouginsFrance
  5. 5.Centre HospitalierDraguignanFrance
  6. 6.Hôpital des BroussaillesCannesFrance